Literature DB >> 11167831

Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment.

F Patriarca1, F Silvestri, R Fanin, F Zaja, A Sperotto, M Baccarani.   

Abstract

Several epidemiological data suggest the involvement of hepatitis C virus (HCV) in the pathogenesis of some histotypes of B-cell non-Hodgkin's lymphomas, in particular immunocytoma. We report a patient with HCV-associated immunocytoma, first treated with six courses of fludarabine. A partial response was achieved and subsequent therapy with alpha-interferon resulted in the clearance of the virus and a long-lasting complete clinical and histological remission of the lymphoproliferative disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11167831     DOI: 10.1046/j.1365-2141.2001.02571.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

Review 1.  Non-Hodgkin lymphoma and hepatitis C: where we are and what next?

Authors:  Mihály Sulyok; Mihály Makara; Eszter Újhelyi; István Vályi-Nagy
Journal:  Pathol Oncol Res       Date:  2014-10-02       Impact factor: 3.201

Review 2.  Hepatitis C virus and non-Hodgkin's lymphomas: Meta-analysis of epidemiology data and therapy options.

Authors:  Gabriele Pozzato; Cesare Mazzaro; Luigino Dal Maso; Endri Mauro; Francesca Zorat; Giulia Moratelli; Pietro Bulian; Diego Serraino; Valter Gattei
Journal:  World J Hepatol       Date:  2016-01-18

Review 3.  Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy.

Authors:  Luca Arcaini; Michele Merli; Stefano Volpetti; Sara Rattotti; Manuel Gotti; Francesco Zaja
Journal:  Clin Dev Immunol       Date:  2012-08-26

Review 4.  Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma.

Authors:  Michele Merli; Giuseppe Carli; Luca Arcaini; Carlo Visco
Journal:  World J Gastroenterol       Date:  2016-10-14       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.